Ligase chain reaction with endonuclease IV correction and contamination control

• US 5,516,663 A
• Filed: 04/19/1993
• Issued: 05/14/1996
• Est. Priority Date: 01/26/1990
• Status: Expired due to Term

• Current Assignee: Abbott Laboratories Incorporated
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Yocum, Robert R., Shimer, George H., Carrino, John J., Backman, Keith C.
• Primary Examiner(s): Jones, W. Gary
• Assistant Examiner(s): Marschel, Ardin H.
• Application Number:
  US08/049,061
• Time in Patent Office: 1,121 Days
• Field of Search: 435/6, 435/91.1, 435/91.2, 436/501, 935/77, 935/78, 536/22.1, 536/23.1, 536/24.1, 536/24.3-24.33
• US Class Current: 435/91.2
• CPC Class Codes: C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• CPC Class Codes: C12N 9/22 Ribonucleases RNAses, DNAses catalytic nucleic acids C12N15/113
• CPC Class Codes: C12Q 1/34 involving hydrolase
• CPC Class Codes: C12Q 1/6848 characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
• CPC Class Codes: C12Q 1/6862 Ligase chain reaction [LCR]
• CPC Class Codes: C12Q 2521/301 Endonuclease
• CPC Class Codes: C12Q 2525/119 incorporating abasic sites
• CPC Class Codes: C12Q 2525/186 incorporating a non-extendable or blocking moiety

Abstract

The present invention involves methods of improving the Ligase Chain Reaction (LCR™) amplification schemes by modifying at least one probe end so that the probability of the probe contributing to spurious ligation and signal development is greatly reduced. Only after specific hybridization of the modified probe with true target are the modified ends "corrected" by endonuclease IV in a target dependent fashion to allow participation of the probe in the enzymatic ligation reaction. Specific modifications include 3'"'"' phosphate blocking groups and nucleic acid overhangs containing an abasic site at the point of ligation. Further embodiments include probes modified to contain ribonucleotide moieties which, after amplification, can be cleaved by RNase to destroy the amplification products and reduce the risk of contamination.

Claims

1. In a ligase chain reaction method for amplifying a target nucleic acid sequence, said method including:

(a) providing at least two sets of two probes, the 3'"'"' end of an upstream probe being ligated to the 5'"'"' end of a downstream probe in the presence of target to form a primary ligation product and the second set of probes hybridizing to the primary ligation product and being ligated to each other to form a secondary ligation product;

(b) repeatedly denaturing the hybridized strands, reannealing additional probes and ligating them; and

(c) detecting to what extent ligation products have formed, the improvement comprising;

(a) providing in at least one of the upstream probes a 3'"'"' end modification such that the probe is incapable of ligation to its downstream partner, said 3'"'"' end modification being correctable substantially only when the modified probe is hybridized to the target sequence;

(b) hybridizing the modified probe to the target, if present, to form a modified probe-template complex;

(c) correcting the modification in a target dependent manner using endonuclease IV activity to create a 3'"'"' hydroxyl end, thus allowing the corrected probe to be ligated to its downstream partner;

(d) ligating the corrected probe to its downstream partner to form an amplification product; and

(e) dissociating the amplification product from the target and repeating the hybridization, correction and ligating steps to amplify the desired target sequence.

2. The method of claim 1 wherein said 3'"'"' modification comprises a blocking moiety attached to said probe such that it blocks a chemical group required in the ligation step.

3. The method of claim 2 wherein the blocking moiety is of the form:

##STR9## wherein Z is selected from the group consisting of --H;

--(CH₂)_n CHO, where n is from 1 to about 3;

-deoxyribose; and

-dideoxyribose.

4. The method of claim 3 wherein said blocking moiety is phosphate.

5. The method of claim 1, wherein at least said correcting step is performed in the presence of available divalent cation selected from cobalt and manganese at a concentration of at least about 0.05 mM.

6. The method of claim 5, wherein said divalent cation is at a concentration from about 0.1 to about 2.0 mM.

7. The method of claim 5, wherein said divalent ion is cobalt at a concentration of about 0.5 mM to about 1.0 mM.

8. The method of claim 5, wherein said divalent ion is manganese at a concentration of about 0.5 mM to about 1.0 mM.

9. The method of claim 1, wherein one or more of the steps is performed in the presence of divalent magnesium ion at a concentration of about 0.5 mM to about 20 mM.

10. The method of claim 1, wherein said two sets of two probes are oligodeoxyribonucleotide probes, except that at least one of said probes includes at least one ribonucleotide residue.

11. The method of claim 10, wherein said at least one ribonucleotide residue occurs immediately 5'"'"' to the 3'"'"' modification.

12. The method of claim 3, wherein said probe having the 3'"'"' end blocking moiety further includes at least one ribonucleotide residue, and the blocking moiety is attached to the 3'"'"' position of said ribonucleotide.

13. The method of claim 10, further comprising, after the detection step, a step of cleaving ligation products using RNase or alkali.

14. The method of claim 10, further comprising, prior to amplification, a step of cleaving ligation products using RNase.

15. The method of claim 14, wherein the blocking moiety is of the form:

##STR10## wherein Z is selected from the group consisting of --H;

--(CH₂)_n CHO, where n is from 1 to about 3;

-deoxyribose; and

-dideoxyribose.

16. The method of claim 2 wherein said blocking moiety is a nucleic acid overhang containing an abasic residue immediately 3'"'"' to the point of intended ligation.

17. The method of claim 16 wherein said correction of the modification comprises cleavage of said modified probe on the 5'"'"' side of said abasic site, substantially only when said modified probe is hybridized to target or to ligation product.

18. The method of claim 16, wherein at least said correcting step is performed in the presence of available divalent cation selected from cobalt and manganese at a concentration of about 0.05 mM to about 2.0 mM.

19. The method of claim 18, wherein said divalent ion is cobalt at a concentration of about 0.5 mM to about 1.0 mM.

20. The method of claim 18, wherein said divalent ion is manganese at a concentration of about 0.5 mM to about 1.0 mM.

21. The method of claim 18, wherein one or more of said steps is performed in the presence of divalent magnesium ion at a concentration of about 0.5 mM to about 20 mM.

22. The method of claim 16, wherein said two sets of two probes are oligodeoxyribonucleotide probes, except that at least one of said probes includes at least one ribonucleotide residue.

23. The method of claim 22, further comprising, after the detection step, a step of cleaving ligation products using RNase or alkali.

24. The method of claim 17, further comprising, prior to amplification, a step of cleaving ligation products using RNase.

25. The method of claim 1, wherein said detecting is by means of a hapten marker attached to the outside ends of the primary upstream and secondary downstream probes and by a reporter or different hapten attached to the outside ends of the primary downstream and secondary upstream probes.

26. The method of claim 25 wherein the reporter is a radioactive, fluorescent or chemiluminescent compound.

27. The method of claim 1 wherein the blocking moiety comprises a detectable label and said detecting is by means of monitoring the release of detectable label from the modified probe.

28. The method of claim 2 wherein said upstream probe containing the 3'"'"' modification and its complementary probe are selected such that, when the two probes are hybridized together, the 5'"'"' terminal residue of the complementary probe lies opposite a nucleotide residue in the upstream probe which is at least one residue 5'"'"' to the site of the modification.

29. The method of claim 16 wherein said upstream probe containing the 3'"'"' abasic site and its complementary probe are selected such that, when the two probes are hybridized together, the 5'"'"' terminal residue of the complementary probe lies opposite a nucleotide residue in the upstream probe which is at least one residue 5'"'"' to the abasic site.

30. A diagnostic kit comprising in combination:

(a) two pairs of probes hybridizable with target, wherein at least one of the probes is modified such that, when hybridized, a ligase is substantially incapable of acting on the modified probe as its substrate, the two probes capable of hybridizing to target in positions such that, upon correction of said modified probe, the two probes can be ligated to one another;

(b) a first enzyme reagent having ligase activity for assembling an amplification product; and

(c) a second enzyme reagent having endonuclease IV activity capable of correcting the modified probe in a target dependent manner to allow the probe-template complex to be acted upon by the ligase reagent.

31. The kit of claim 30, further including a buffer or means for preparing a buffer containing from 0.05 mM to about 2.0 mM of divalent cobalt ion.

32. The kit of claim 30, further including an RNase reagent or an alkaline reagent.

33. The kit of claim 30 wherein the first enzyme reagent, the second enzyme reagent, or both, are thermostable.

34. The kit of claim 30 wherein the second enzyme reagent comprises Endonuclease IV.

35. A nucleic acid probe having at least three deoxyribonucleotides covalently linked by phosphodiester linkages to define a probe having an available 3'"'"' position, the probe further comprising a ribonucleotide attached at the 3'"'"' position, the ribonucleotide having a further 3'"'"' position to which is attached a group of the formula:

##STR11## wherein Z is selected from the group consisting of --H;

--(CH₂)_n CHO, where n is from 1 to about 3;

-deoxyribose; and

-dideoxyribose.

36. The probe of claim 35 wherein Z is hydrogen.

37. The probe of claim 35 having about 12 to about 50 deoxyribonucleotides.

38. A nucleic acid probe composition comprising a nucleic acid probe according to claim 35 in a buffer.

39. The probe composition of claim 38 wherein Z is hydrogen.

40. The probe composition of claim 38 having about 12 to about 50 deoxyribonucleotides.